Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 31 staff and has a market cap (total outstanding shares value) of USD$573.1 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$3.46 - USD$9 |
---|---|
50-day moving average | USD$4.1314 |
200-day moving average | USD$4.902 |
Wall St. target price | USD$4.72 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.594 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -30.75% |
Return on equity TTM | -51.91% |
Profit margin | 0% |
Book value | $1.337 |
Market capitalisation | USD$573.1 million |
TTM: trailing 12 months
There are currently 2.2 million Aptose Biosciences shares held short by investors – that's known as Aptose Biosciences's "short interest". This figure is 1.7% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Aptose Biosciences shares can be evaluated.
Aptose Biosciences's "short interest ratio" (SIR) is the quantity of Aptose Biosciences shares currently shorted divided by the average quantity of Aptose Biosciences shares traded daily (recently around 1.0 million). Aptose Biosciences's SIR currently stands at 2.17. In other words for every 100,000 Aptose Biosciences shares traded daily on the market, roughly 2170 shares are currently held short.
However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptose Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aptose Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0254% of the tradable shares (for every 100,000 tradable Aptose Biosciences shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptose Biosciences.
Find out more about how you can short Aptose Biosciences stock.
We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.
Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.
Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $3.46 up to $9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.1254. This would suggest that Aptose Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.